domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
+
+### Additional Evidence (extend)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
+
+FLOW trial provides the strongest per-patient cost-savings mechanism for GLP-1s: preventing progression to dialysis ($90K+/year per patient). Slowing eGFR decline by 1.16 mL/min/1.73m2 annually could delay or prevent dialysis for many patients. CKD is among the most expensive chronic conditions to manage, making kidney protection the most economically favorable indication for the value-based care thesis, even if net costs remain inflationary through 2035 due to chronic use model.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -36,6 +36,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 
 SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems.
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
+
+FLOW trial demonstrated simultaneous benefits: 24% reduction in kidney disease progression, 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89), and 18% lower risk of major cardiovascular events. The trial was designed as a kidney outcomes study but captured significant cardiovascular mortality benefits, demonstrating that organ protection effects compound across systems. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors.
+
 ---
 
 Relevant Notes:

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 - FDA indication expansion to T2D patients with CKD (2024)
 - Dialysis cost benchmark: $90K+/year per patient
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
+
+FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR slope improvement of 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early for efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, providing the highest-quality evidence (NEJM publication, randomized controlled trial) for kidney protection.
+
 ---
 
 Relevant Notes:

inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md

@@ -7,9 +7,13 @@ date: 2024-05-29
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -38,3 +42,12 @@ Additive benefits when used with SGLT2 inhibitors (separate analysis in Nature M
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Kidney protection is where GLP-1 downstream savings are largest per-patient — dialysis prevention is the economic mechanism most favorable to the VBC cost-saving thesis
 EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for capitated payers, not just the clinical endpoint
+
+
+## Key Facts
+- FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease
+- Median follow-up was 3.4 years before early stopping
+- Primary composite endpoint showed HR 0.76 (P=0.0003) for major kidney disease events
+- Annual eGFR slope difference was 1.16 mL/min/1.73m2 (P<0.001)
+- Cardiovascular death HR was 0.71 (95% CI 0.56-0.89)
+- Dialysis costs approximately $90,000+ per year per patient in the US